Handwriting movement analyses for monitoring drug-induced motor side effects in schizophrenia patients treated with risperidone.
Epidemiologic studies indicate that nearly 60% of schizophrenia (SZ) patients treated with conventional antipsychotic drugs develop extrapyramidal side effects (EPS) such as parkinsonism and tardive dyskinesia. Although the prevalence of EPS has decreased due to the newer antipsychotics, EPS continue to limit the effectiveness of these medicines. Ongoing monitoring of EPS is likely to improve treatment outcome or compliance and reduce the frequency of re-hospitalization. A quantitative analysis of handwriting kinematics was used to evaluate effects of antipsychotic medication type and dose in schizophrenia patients. Twenty-seven schizophrenia patients treated with risperidone, six schizophrenia patients who received no antipsychotic medication and 47 healthy comparison participants were enrolled. Participants performed a 20-min handwriting task consisting of loops of various sizes and a sentence. Data were captured and analyzed using MovAlyzeR software. Results indicated that risperidone-treated participants exhibited significantly more dysfluent handwriting movements than either healthy or untreated SZ participants. Risperidone-treated participants exhibited lower movement velocities during production of simple loops compared to unmedicated patients. Handwriting dysfluency during sentence writing increased with dose. A 3-factor model consisting of kinematic variables derived from sentence writing accounted for 83% (r=.91) of the variability in medication dose. In contrast, we found no association between observer-based EPS severity ratings and medication dose. These findings support the importance of handwriting-based measures to monitor EPS in medicated schizophrenia patients.
Caligiuri
Michael P
MP
Department of Psychiatry (0603), University of California, La Jolla, CA 92093, USA. mcaligiuri@ucsd.edu
Teulings
Hans-Leo
HL
Dean
Charles E
CE
Niculescu
Alexander B
AB
Lohr
James
J
D000328:Adult; D017668:Age of Onset; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use; D016001:Confidence Intervals; D003863:Depression / Q000188:drug therapy / Q000503:physiopathology / Q000523:psychology; D016903:Drug Monitoring / Q000379:methods*; D020820:Dyskinesias / Q000188:drug therapy / Q000503:physiopathology / Q000523:psychology; D005260:Female; D006236:Handwriting; D006801:Humans; D007700:Kinetics; D008297:Male; D008875:Middle Aged; D008991:Monitoring, Physiologic / Q000379:methods; D012016:Reference Values; D018967:Risperidone / Q000009:adverse effects* / Q000627:therapeutic use*; D012559:Schizophrenia / Q000188:drug therapy* / Q000503:physiopathology; D012565:Schizophrenic Psychology; D012984:Software
D014150:Antipsychotic Agents; D018967:Risperidone
Schizophr Res. 1990 Jul-Aug;3(4):247-51
2278986
Pharmacopsychiatry. 1991 Jul;24(4):132-7
1754609
Am J Psychiatry. 1993 Sep;150(9):1343-8
8352344
Schizophr Bull. 1987;13(2):261-76
3616518
Drugs Aging. 2000 Nov;17(5):363-84
11190417
Psychiatry Res. 1999 Feb 22;90(1):31-9
10320209
Rev Can Biol. 1961 Jun;20:425-49
13903363
Biol Psychiatry. 1997 Apr 1;41(7):830-3
9084903
Hum Mov Sci. 2006 Oct;25(4-5):510-22
16647772
Schizophr Res. 2005 Jun 1;75(1):65-75
15820325
Acta Psychiatr Belg. 1978 Jan-Feb;78(1):19-36
645405
J Clin Psychiatry. 2007;68 Suppl 6:10-3
17650054
Exp Neurol. 1997 Jul;146(1):159-70
9225749